- Home
- GNTA vs LTRN Comparison
GNTA vs LTRN Comparison
Compare GNTA & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | LTRN |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 31.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNTA | LTRN |
|---|---|---|
| Price | $0.88 | $2.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 53.4K | 46.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $2.45 |
| 52 Week High | $10.00 | $5.74 |
Technical Indicators
Market Signals| Indicator | GNTA | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 32.85 |
| Support Level | $0.71 | N/A |
| Resistance Level | $1.70 | $3.65 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 17.75 | 6.67 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.